Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IMA402 in Recurrent and/or Refractory Solid Tumors
NCT05958121Phase 2Recruiting
- Sponsor
- Immatics
- Start
- Aug 2023
- Primary completion
- Sep 2027
- Modality
- Bispecific Antibodies, T-cell Engagers
- Countries
- 2
01
Overview
A Phase 2 trial of IMA402 in solid tumor, sponsored by Immatics. Started Aug 2023; status: recruiting.
02
Drugs
IMA402
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT05958121.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05958121.